|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
SomaticCausalMutation
|
disease |
ORPHANET |
Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor.
|
12112524 |
2002 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Prognostic significance of NPM-ALK fusion transcript overexpression in ALK-positive anaplastic large-cell lymphoma.
|
17464320 |
2007 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
While the expression of SALL4 is normally restricted to ESCs and somatic stem cells, we found that it is aberrantly expressed in ALK-positive anaplastic large cell lymphoma (ALK+ ALCL), a type of lymphoid malignancy carrying a mature T-cell immunophenotype. shRNA knockdown of SALL4 in ALK+ ALCL cell lines resulted in apoptosis and cell-cycle arrest, and significantly decreased colony formation on soft agar.
|
22743134 |
2012 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Since the discovery of ALK-positive anaplastic large-cell lymphoma in 1994 many other types of tumors showing ALK expression were disclosed.
|
24490615 |
2014 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we describe a novel truncated form of the ALK transcript with in-frame skipping through exons 2 to 17 (ALKΔ2-17) in anaplastic large cell lymphoma, ALK-positive.
|
28665006 |
2018 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma.
|
16709933 |
2006 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
Biomarker
|
disease |
BEFREE |
The fusion tyrosine kinase NPM-ALK is central to the pathogenesis of ALK-positive anaplastic large cell lymphoma (ALK(+)ALCL).
|
21703420 |
2011 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
|
24509625 |
2014 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overexpression of c-myc has been shown to be a consistent finding in ALK+, but not ALK-negative ALCL (ALK- ALCL), and the c-myc gene is considered a downstream target of deregulated ALK signaling.
|
16955462 |
2007 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
Biomarker
|
disease |
BEFREE |
We studied the prognostic value of minimal disseminated disease (MDD) and anti-ALK immune response in children with NPM-ALK-positive anaplastic-large cell lymphoma (ALCL) and evaluated their potential for risk stratification.
|
22907048 |
2013 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
Biomarker
|
disease |
BEFREE |
ALK- ALCL lacks ALK protein expression, but expresses CD30 and has morphologic features similar to ALK positive anaplastic large cell lymphoma (ALK+ ALCL).
|
31072226 |
2019 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
Biomarker
|
disease |
BEFREE |
It induced concentration-dependent growth inhibition/cytotoxicity of ALK-positive anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma cells, and displayed dose-dependent inhibition of ALK tyrosine phosphorylation in tumor xenografts in mice, with substantial target inhibition (>90%) for more than 12 hours following single oral dosing at 30 mg/kg.
|
22203728 |
2012 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma.
|
29642597 |
2018 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, the homogenous category of ALK lymphoma ('ALKoma') has emerged as a distinct pathological entity within the heterogenous group of ALCL.
|
10994999 |
2000 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that lymphomas carrying variants of the NPM-ALK fusion protein can be detected by immunostaining for ALK and NPM and also that they can be grouped with classical t(2;5)-positive tumors as a single entity (ALK-positive lymphoma or "ALKoma") that shows a better prognosis than ALK-negative anaplastic large-cell lymphoma.
|
10552961 |
1999 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
Biomarker
|
disease |
BEFREE |
STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
|
25921060 |
2015 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
Biomarker
|
disease |
BEFREE |
I propose that tumors carrying abnormal ALK as an essential growth driver be collectively termed "ALKoma."
|
22614325 |
2012 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
Biomarker
|
disease |
BEFREE |
Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
|
26133723 |
2016 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cellular immune responses against the oncoantigen anaplastic lymphoma kinase (ALK) in patients with ALK-positive anaplastic large cell lymphoma (ALCL) have been detected using peptide-based approaches in individuals preselected for human leucocyte antigen (HLA)-A*02:01.
|
27414060 |
2016 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have previously shown that treatment of ALK-positive anaplastic large cell lymphoma cells with the ALK tyrosine kinase inhibitor crizotinib induces autophagy as a pro-survival response.
|
30679328 |
2019 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
Biomarker
|
disease |
BEFREE |
To illustrate and study cancer cell plasticity in hematopoietic cancers, we employed an in-vitro experimental model of ALK-positive anaplastic large-cell lymphoma (ALK+ALCL) that is based on the phenotypic and functional dichotomy of these cells, with cells responsive to a Sox2 reporter (i.e.
|
29609590 |
2018 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
Biomarker
|
disease |
BEFREE |
First, the 'anaplastic large cell lymphoma, ALK positive' (ALK(+) ALCL) that is characterized by the presence of ALK gene rearrangements and consequent ALK protein expression, and, second, the 'anaplastic large cell lymphoma, ALK negative' (ALK(-) ALCL) that is a provisional entity lacking ALK protein expression but cannot be distinguished morphologically from ALK(+) ALCL.
|
25559471 |
2015 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we used subtractive suppression hybridization to compare gene expression between an ALK-positive anaplastic large cell lymphoma (ALCL)-derived cell line and a clinical case of ALK-negative ALCL.
|
12181047 |
2002 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
Biomarker
|
disease |
BEFREE |
NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma.
|
31428523 |
2019 |
|
Anaplastic Large Cell Lymphoma, ALK-Positive
|
0.400 |
Biomarker
|
disease |
BEFREE |
Identification of a novel crosstalk between casein kinase 2α and NPM-ALK in ALK-positive anaplastic large cell lymphoma.
|
23153582 |
2013 |